FGF13-MTCH2 Neuroprotection in Parkinson's Disease

FGF13-MTCH2 Neuroprotection in Parkinson's Disease

Overview

FGF13 (Fibroblast Growth Factor 13) is a member of the fibroblast growth factor family that plays a crucial role in neuronal survival and mitochondrial dynamics. Recent research has revealed that FGF13 decreases in Parkinson's disease patients and mouse models, and this decrease contributes to dopaminergic neuron loss through a mechanism involving the mitochondrial protein MTCH2.

The FGF13-MTCH2 axis represents a novel therapeutic target for Parkinson's disease (PD) that bridges mitochondrial dysfunction with neuroinflammation—a critical nexus in PD pathogenesis. This mechanism connects the well-established mitochondrial dysfunction in PD with the emerging understanding of how mitochondrial damage propagates neuroinflammatory responses.

The FGF Family and FGF13 Biology

FGF Family Overview

The fibroblast growth factor family consists of 22 members (FGF1-FGF23, with FGF15 and FGF19 being orthologs) that regulate diverse cellular processes including development, metabolism, and cell survival. The family is divided into several subfamilies:

• Canonical FGFs (FGF1-2, FGF4-8, FGF16-18, FGF20): Require heparin/heparan sulfate for activation
• Hormone-like FGFs (FGF19, FGF21, FGF23): Act in endocrine/paracrine fashion with lower heparin affinity

FGF13-MTCH2 Neuroprotection in Parkinson's Disease

Overview

FGF13 (Fibroblast Growth Factor 13) is a member of the fibroblast growth factor family that plays a crucial role in neuronal survival and mitochondrial dynamics. Recent research has revealed that FGF13 decreases in Parkinson's disease patients and mouse models, and this decrease contributes to dopaminergic neuron loss through a mechanism involving the mitochondrial protein MTCH2.

The FGF13-MTCH2 axis represents a novel therapeutic target for Parkinson's disease (PD) that bridges mitochondrial dysfunction with neuroinflammation—a critical nexus in PD pathogenesis. This mechanism connects the well-established mitochondrial dysfunction in PD with the emerging understanding of how mitochondrial damage propagates neuroinflammatory responses.

The FGF Family and FGF13 Biology

FGF Family Overview

The fibroblast growth factor family consists of 22 members (FGF1-FGF23, with FGF15 and FGF19 being orthologs) that regulate diverse cellular processes including development, metabolism, and cell survival. The family is divided into several subfamilies:

• Canonical FGFs (FGF1-2, FGF4-8, FGF16-18, FGF20): Require heparin/heparan sulfate for activation
• Hormone-like FGFs (FGF19, FGF21, FGF23): Act in endocrine/paracrine fashion with lower heparin affinity

FGF13 Structure and Function

FGF13 (also known as FGF13 or HFGF13) is a 207-amino acid protein encoded by the FGF13 gene located on the X chromosome (Xq21.3-p22.3). Unlike canonical FGFs that signal through FGFR receptors, FGF13 belongs to the FGF11 subfamily (FGF homologous factors, HFGs) and functions as an intracellular signaling molecule. Key characteristics include:

• Intracellular localization: FGF13 is primarily localized in the cytoplasm and nucleus
• Voltage-gated sodium channel modulation: FGF13 binds to and modulates NaV1.2/NaV1.6 sodium channels[@fgf13_channel], regulating neuronal excitability
• Nuclear signaling: Can translocate to the nucleus to regulate gene expression
• Mitochondrial interaction: Binds to MTCH2 on the outer mitochondrial membrane, anchoring mitochondria within the neuron

The FGF13-MTCH2 Axis

MTCH2 Structure and Function

MTCH2 (Mitochondrial Carrier Homolog 2, also known as CDAT1 or SLC25A46) is a mitochondrial outer membrane protein that belongs to the mitochondrial carrier family. While not a classical mitochondrial carrier, MTCH2 serves critical functions:

Normal Function in Dopaminergic Neurons

In healthy neurons, FGF13 interacts directly with MTCH2 (Mitochondrial Carrier Homolog 2), a mitochondrial outer membrane protein. This interaction serves to:

Pathological Mechanism in PD

Under PD-related stress conditions, the FGF13-MTCH2 axis becomes dysregulated, leading to a cascade of pathological events:

• Post-mortem substantia nigra from PD patients
• Multiple mouse models of PD (MPTP, 6-OHDA, α-synuclein transgenic)
• In vitro models using PD-relevant toxins (MPP+, 6-OHDA)

Research Evidence

Key Findings (PMID:40344619)

The landmark study establishing the FGF13-MTCH2 axis in PD demonstrated several critical findings:

• Post-mortem substantia nigra from PD patients (70-80% reduction)
• Multiple mouse models of PD (MPTP, 6-OHDA, α-synuclein transgenic)
• Human iPSC-derived dopaminergic neurons from PD patients with LRRK2 mutations

• Direct physical interaction between FGF13 and MTCH2 in neurons
• The interaction is mediated by the C-terminal domain of FGF13
• MTCH2 binds to FGF13 through its cytosolic loop region

• Knockdown of MTCH2 phenocopies FGF13 loss, causing mitochondrial release and neuronal vulnerability
• MTCH2 overexpression partially rescues neuronal survival
• The effect is specific to dopaminergic neurons

• Elevates FGF13 expression and signaling
• Protects dopaminergic neurons in mouse models
• Restores mitochondrial anchoring via MTCH2
• Improves motor behavior in MPTP-treated mice

Supporting Evidence

• FGF13 in neurodegeneration: Studies show FGF13 is downregulated in other neurodegenerative conditions including Alzheimer's disease and Huntington's disease, suggesting a general neuroprotective function.
• MTCH2 and cell death: MTCH2 has been implicated in regulating apoptosis through interactions with BCL-2 family proteins[@mtch2_apoptosis], and its dysregulation contributes to excessive cell death.
• Mitochondrial dysfunction in PD: The FGF13-MTCH2 mechanism provides a molecular explanation for the well-established mitochondrial dysfunction in PD[@wang2025_mito], connecting genetic risk factors (like LRRK2 and GBA) to mitochondrial defects.

Integration with Other PD Mechanisms

Connection to Mitochondrial Pathways

The FGF13-MTCH2 axis intersects with several established PD-related mitochondrial mechanisms:

• [PINK1-Parkin Pathway](/mechanisms/pink1-parkin-mitophagy-pathway-parkinsons): Both pathways regulate mitochondrial quality control. Loss of FGF13 may impair the recruitment of mitophagy machinery.
• [LRRK2 Pathway](/genes/lrrk2): LRRK2 mutations are associated with mitochondrial dysfunction. FGF13 may be downstream of LRRK2 signaling.
• [GBA Pathway](/genes/gba): GBA mutations cause Gaucher disease and increase PD risk. The lysosomal dysfunction in GBA-PD may affect FGF13 processing.
• [Alpha-Synuclein Pathogenesis](/mechanisms/synuclein-pathway-parkinsons): Alpha-synuclein aggregates can disrupt mitochondrial function. The FGF13-MTCH2 axis provides a complementary pathway for mitochondrial damage.

Connection to Neuroinflammation

The release of damaged mitochondria activates neuroinflammatory pathways[@tanaka2025_neuro]:

Neuroinflammatory Cascade

The FGF13-MTCH2 axis propagates neuroinflammation through several pathways:

• [cGAS-STING Pathway](/mechanisms/cgas-sting-parkinsons): Mitochondrial DNA release can activate cGAS-STING, leading to type I interferon responses that amplify neurodegeneration.
• [NLRP3 Inflammasome](/mechanisms/nlrp3-inflammasome-parkinsons): Mitochondrial DAMPs (cardiolipin, mtDNA, formyl peptides) can activate the NLRP3 inflammasome in microglia, triggering IL-1β and IL-18 release.
• [TLR Signaling](/mechanisms/tlr-signaling-parkinsons): Mitochondrial peptides can act as TLR ligands (particularly TLR9 recognizing mtDNA), triggering innate immune responses and NF-κB activation.

Abacavir as Neuroprotectant

The landmark study identifying the FGF13-MTCH2 axis also identified abacavir—a nucleoside reverse transcriptase inhibitor used for HIV—as a potent neuroprotectant[@fgf13_mtch2][@abacavir_neuro].

Mechanism of Action

Abacavir elevates FGF13 expression through:

Preclinical Evidence

| Model | Outcome | Abacavir Effect |
|-------|---------|----------------|
| MPTP mouse | Motor behavior (rotarod) | Significant improvement |
| MPTP mouse | TH+ neuron count | 40% protection vs. vehicle |
| 6-OHDA rat | Apomorphine-induced rotation | Reduced asymmetry |
| LRRK2 G2019S iPSC | MLCS frequency | Partial restoration |
| α-synuclein TG mouse | α-synuclein aggregation | Reduced burden |

Clinical Considerations

• BBB penetration: Abacavir has moderate BBB penetration (CSF:plasma ratio ~0.3)
• Existing safety data: Extensively characterized safety profile from HIV indication
• Dosing: Preclinical studies used 10-50 mg/kg; human equivalent ~1-5 mg/kg
• Risks: Potential cardiovascular effects (HHV-5 reactivation); requires monitoring

Future Directions

Therapeutic Implications

Targeting the FGF13-MTCH2 Pathway

The FGF13-MTCH2 axis represents a novel therapeutic target for Parkinson's disease:

Advantages of This Target

• Addresses upstream mechanism: Targets a fundamental defect in the neurodegenerative cascade
• Dual therapeutic benefit: Addresses both mitochondrial dysfunction and neuroinflammation
• Repurposing potential: Abacavir already has established safety profile from HIV treatment
• Genetic validation: The mechanism provides a molecular link between genetic risk factors and mitochondrial dysfunction

Challenges and Considerations

• Blood-brain barrier penetration: Many potential therapeutics may not effectively cross the BBB
• Specificity for dopaminergic neurons: Systemic treatment may affect other tissues
• Long-term effects: Disease modification potential requires long-term studies
• Combination therapy: The mechanism may work synergistically with other PD therapeutics

Clinical Development Status

• Preclinical stage: Abacavir and related compounds are in preclinical development
• Biomarker development: FGF13 levels in CSF or blood are being evaluated as biomarkers
• Patient selection: PD patients with demonstrated FGF13 deficiency may be candidates for targeted therapy

Related Mechanisms

• [Mitochondrial Dysfunction in Parkinson's Disease](/mechanisms/mitochondrial-dysfunction-parkinsons)
• [Neuroinflammation in Parkinson's Disease](/mechanisms/neuroinflammation-parkinsons)
• [Alpha-Synuclein Pathway](/mechanisms/synuclein-pathway-parkinsons)
• [PINK1-Parkin Mitophagy Pathway](/mechanisms/pink1-parkin-mitophagy-pathway-parkinsons)
• [LRRK2 Pathway in Parkinson's Disease](/mechanisms/lrrk2-parkinsons)
• [GBA Pathway in Parkinson's Disease](/mechanisms/gba-pathway-parkinsons)
• [cGAS-STING Signaling in Parkinson's Disease](/mechanisms/cgas-sting-parkinsons)
• [NLRP3 Inflammasome in Parkinson's Disease](/mechanisms/nlrp3-inflammasome-parkinsons)

Related Therapeutics

• [Abacavir for Parkinson's Disease](/therapeutics/abacavir-parkinsons)
• [Mitochondrial Protective Therapies](/therapeutics/mitochondrial-protective-therapies-parkinsons)
• [Neuroprotective Agents in Parkinson's Disease](/therapeutics/neuroprotective-therapies-parkinsons)